Cure8 research brief
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Clinicians treating IBD, researchers studying IBD biomarkers or microbiome–host interactions, and adult patients interested in new noninvasive markers for disease activity.
This retrospective clinic-based study measured fecal GP2 by ELISA in 87 people with CD, 58 with UC, and 31 healthy controls, and related levels to clinical activity, standard inflammatory markers (CRP, fecal calprotectin, elastase), response to induction biologic therapy, and gut microbiome profiles using 16S sequencing.
The key findings reported in the abstract are: fecal GP2 was significantly reduced in UC versus CD and controls, with the lowest levels in active UC; fecal GP2 did not differ from controls in CD but correlated with fecal elastase activity; fecal GP2 increased after induction therapy among clinical responders; and fecal GP2 levels associated with gut microbial diversity.
Serum anti-GP2 antibodies did not correlate with fecal GP2 or treatment response.
Results are from a retrospective cohort and summarized in the PubMed abstract; findings need prospective replication and formal validation before clinical application.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...
